MetLife Investment Management’s CorMedix CRMD Stock Holding History

MetLife Investment Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$274K	Sell	40,399 -870	-2%	-$6.43K	﹤0.01%	2056
2025 Q4	$480K	Buy	41,269 +314	+0.8%	+$3.47K	﹤0.01%	1808
2025 Q3	$476K	Buy	40,955 +4,317	+12%	+$52.2K	﹤0.01%	1826
2025 Q2	$451K	Buy	36,638 +246	+0.7%	+$2.72K	﹤0.01%	1726
2025 Q1	$224K	Sell	36,392 -3,023	-8%	-$31.3K	﹤0.01%	2135
2024 Q4	$319K	Buy	39,415 +3,776	+11%	+$37.7K	﹤0.01%	2041
2024 Q3	$288K	Hold	35,639	–	–	﹤0.01%	2084
2024 Q2	$154K	Buy	35,639 +8,785	+33%	+$44.6K	﹤0.01%	2397
2024 Q1	$114K	Buy	26,854 +3,149	+13%	+$10.9K	﹤0.01%	2472
2023 Q4	$89.1K	Hold	23,705	–	–	﹤0.01%	2653
2023 Q3	$87.7K	Hold	23,705	–	–	﹤0.01%	2642
2023 Q2	$94K	Buy	+23,705	New	+$117K	﹤0.01%	2715

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

MetLife Investment Management's CRMD Position: Q1 2026 in Review

MetLife Investment Management reduced its CorMedix (CRMD) stake by 2.1% in Q1 2026, selling an estimated $6.43K and leaving 40,399 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

MetLife Investment Management first reported a position in CRMD in Q2 2023 and has held it in 12 quarters since. The position peaked at $480K in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

MetLife Investment Management held 40,399 shares of CorMedix worth $274K as of Q1 2026.
MetLife Investment Management sold 870 CorMedix shares in Q1 2026, an estimated $6.43K.
CorMedix made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2056 holding.
MetLife Investment Management first reported a position in CorMedix in Q2 2023 and has held it in 12 quarters since.
MetLife Investment Management's CorMedix position peaked at $480K in Q4 2025.
187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.